Anastassios Pittas, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1508976036
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,120 of the $3,136 with a category attached, or 99.5%. Azurity Pharmaceuticals, Inc. accounts for 99.5% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $1045.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Azurity Pharmaceuticals, Inc.$3K
- Cequr Corporation$16
Across 21 payments — averaging $11,808 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$246K
- AbbVie$1K
What the payments were for
- Speaking & faculty fees$3,12099%
- Food & beverage$161%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Azurity Pharmaceuticals, Inc. | 2 | $3,120 |
| Cequr Corporation | 1 | $16 |
How this compares
$3,136 in reported general payments places this provider in the 70th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $62,821 |
| TrulicityDulaglutide | 36 | $60,931 |
| AfrezzaInsulin Regular, Human | 12 | $33,856 |
| MounjaroTirzepatide | 19 | $23,059 |
| JanuviaSitagliptin Phosphate | 12 | $12,075 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $9,604 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 20 | $3,676 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,989 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,816 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 16 | $1,657 |
| Levothyroxine Sodium | 38 | $588 |
| Atorvastatin Calcium | 19 | $300 |
| Metformin Hcl | 27 | $162 |
| Losartan Potassium | 19 | $91 |
| Pioglitazone Hcl | 12 | $60 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Augusto Caballero-RoblesBoston$150K
- Osama HamdyBoston$117K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.